Clinical Policy: Suzetrigine (Journavx)
Customize your policy alerts
Sign up for Ambetter Georgia Policy CP.PMN.301 alerts
Get alerted when Policy CP.PMN.301 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and prior authorization criteria for suzetrigine (Journavx) for adults with moderate to severe acute pain, including postoperative pain, across Ambetter Georgia lines of business.
Updated FDA approved indication to include postoperative pain per prescribing information.
Added ICHRA (health insurance marketplace/ICHRA) as a line of business.
Added step therapy bypass for Illinois HIM requests per IL HB 5395.
Coverage Criteria
Initial Therapy
Covered when ALL of the following are met:
Step therapy bypass for Illinois HIM per IL HB 5395
Continuation Therapy
Covered when ALL of the following are met:
Approval duration: 14 days
Requests for uses of Suzetrigine (Journavx) that are outside the FDA‑approved indications and are not specifically addressed in this policy will not be authorized unless the provider supplies sufficient documentation of efficacy and safety consistent with the referenced off‑label use policies. See off‑label use policies: CP.CPA.09 (Commercial), HIM.PA.154 (Health Insurance Marketplace / ICHRA), and CP.PMN.53 (Medicaid) for the criteria used to evaluate off‑label requests.
Requests for non‑FDA‑approved uses of Journavx that lack sufficient supporting evidence as defined by the referenced off‑label policies are considered not authorized. Providers should consult and document compliance with the applicable off‑label use policy (see CP.CPA.09, HIM.PA.154, and CP.PMN.53) when submitting such requests.
Initial Therapy
Initial Therapy
Covered when ALL of the following are met:
Step therapy bypass for Illinois HIM per IL HB 5395
Continued Therapy
Continued Therapy
Covered when ALL of the following are met:
Approval duration: 14 days
Provider Actions & Prior Authorization
Prior authorization required; 14-day approval
Prior authorization is required for suzetrigine (Journavx). When all approval criteria are met, authorization is granted for a maximum duration of 14 days for both initial and continued therapy.
Step therapy: failure of ≥2 analgesics; IL HIM bypass
Step therapy requires documented failure of at least two analgesic medications unless clinically significant adverse effects or contraindications exist. For Illinois HIM requests, the step therapy requirements do not apply as of 1/1/2026 per IL HB 5395.
- Failure of ≥ 2 analgesic medications (e.g., NSAIDs, aspirin, acetaminophen, tramadol, opioids) is required prior to approval unless contraindicated or adverse effects prohibit use.
- Step therapy bypass applies to Illinois HIM requests effective 1/1/2026 per IL HB 5395.
Submit office notes, labs, or other clinical records
Provider must submit supporting clinical documentation with the prior authorization request to demonstrate the member meets all approval criteria.
- Acceptable documentation includes office chart notes, lab results, or other clinical information.
- Documentation should substantiate diagnosis (moderate to severe acute pain), age, relevant surgical/trauma history or failed analgesic trials, multimodal analgesia use, and prescribed dosing within policy limits.
Denial triggers: missing docs or unsupported off‑label use
Requests may be denied if required documentation is missing or if the request is for a non–FDA-approved indication without sufficient evidence as required by the off-label use policies.
- Missing supporting documentation that the member meets the policy’s approval criteria is a denial trigger.
- Requests for non‑FDA‑approved indications not addressed in this policy will be denied unless sufficient documentation of efficacy and safety is provided per CP.CPA.09 (Commercial), HIM.PA.154 (HIM/ICHRA), or CP.PMN.53 (Medicaid).
Step Therapy Requirements
| Required prior therapeutic(s) / exception | Notes |
|---|---|
| Failure of at least two analgesic medications (e.g., NSAIDs, aspirin, acetaminophen, tramadol, opioids) | Required prior to approval unless contraindicated or clinically significant adverse effects are experienced. |
| Recent (within the last 7 days) major surgery or traumatic injury (e.g., crush injuries, spinal cord injury, burns, broken or dislocated bones) | Meets initial-therapy pathway; counts as qualifying condition in lieu of step therapy failure. |
| Planned surgical procedure with either (i) risk factors for increased post-operative pain or (ii) procedure classified as major and associated with moderate to severe post-operative pain | Meets initial-therapy pathway; counts as qualifying condition in lieu of step therapy failure. |
| IL HIM (Illinois Health Insurance Marketplace) requests | Step therapy requirements do not apply for Illinois HIM requests per IL HB 5395 (effective 1/1/2026). |
| Exceptions for clinical contraindication or clinically significant adverse effects to recommended analgesics | If contraindicated or adverse effects prevent use of alternatives, step therapy requirement is waived; provider documentation required. |
Coding & Dosing Limits
Quantity Limits
Site of Care
Home/outpatient use allowed; no site restrictions
No site‑of‑care restrictions are stated; intended for outpatient oral administration as part of multimodal analgesia and may be used at home when criteria are met.
Definitions
Background
Suzetrigine (Journavx) is a selective sodium channel blocker approved for the treatment of moderate to severe acute pain, including postoperative pain, in adults. The product is intended as part of multimodal analgesia and dosing guidance includes a higher initial dose on day 1 followed by a lower maintenance dose thereafter; prior authorization and duration limits apply per policy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.